WO1996012742A1 - Binding agents for treatment of inflammatory, autoimmune or allergic diseases - Google Patents
Binding agents for treatment of inflammatory, autoimmune or allergic diseases Download PDFInfo
- Publication number
- WO1996012742A1 WO1996012742A1 PCT/EP1995/004110 EP9504110W WO9612742A1 WO 1996012742 A1 WO1996012742 A1 WO 1996012742A1 EP 9504110 W EP9504110 W EP 9504110W WO 9612742 A1 WO9612742 A1 WO 9612742A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- binding agent
- binding
- agent according
- cd11c
- cd11b
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6432—Coagulation factor Xa (3.4.21.6)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/7056—Lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21006—Coagulation factor Xa (3.4.21.6)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
- C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Biotechnology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR9509434A BR9509434A (en) | 1994-10-25 | 1995-10-20 | Agglutination agent use of the same pharmaceutical composition and process of treatment of an autoimmune or allergic inflammatory disease |
NZ295352A NZ295352A (en) | 1994-10-25 | 1995-10-20 | Use of binding agents like antibodies for inhibiting cd23 in treating prophylaxis of autoimmune diseases |
AU38679/95A AU710369B2 (en) | 1994-10-25 | 1995-10-20 | Binding agents for treatment of inflammatory, autoimmune or allergic diseases |
EP95937803A EP0788514A1 (en) | 1994-10-25 | 1995-10-20 | Binding agents for treatment of inflammatory, autoimmune or allergic diseases |
JP8513642A JPH10507460A (en) | 1994-10-25 | 1995-10-20 | Binding substances for treating inflammation, autoimmune diseases and allergic diseases |
MXPA/A/1997/002772A MXPA97002772A (en) | 1994-10-25 | 1997-04-16 | Linking agents for the treatment of inflammatory, autoimmune or alergi treatments |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9421463A GB9421463D0 (en) | 1994-10-25 | 1994-10-25 | Binding agents |
GB9421463.2 | 1994-10-25 | ||
GB9512480.6 | 1995-06-20 | ||
GBGB9512480.6A GB9512480D0 (en) | 1995-06-20 | 1995-06-20 | Binding agents |
GBGB9513415.1A GB9513415D0 (en) | 1995-06-30 | 1995-06-30 | Binding agents |
GB9513415.1 | 1995-06-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996012742A1 true WO1996012742A1 (en) | 1996-05-02 |
Family
ID=27267444
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1995/004110 WO1996012742A1 (en) | 1994-10-25 | 1995-10-20 | Binding agents for treatment of inflammatory, autoimmune or allergic diseases |
PCT/EP1995/004109 WO1996012741A1 (en) | 1994-10-25 | 1995-10-20 | Binding agents to cd23 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1995/004109 WO1996012741A1 (en) | 1994-10-25 | 1995-10-20 | Binding agents to cd23 |
Country Status (21)
Country | Link |
---|---|
US (2) | US6627195B1 (en) |
EP (3) | EP1018517A3 (en) |
JP (3) | JPH10507460A (en) |
KR (1) | KR20040058016A (en) |
CN (1) | CN1171119A (en) |
AT (1) | ATE198895T1 (en) |
AU (2) | AU710369B2 (en) |
BR (2) | BR9509498A (en) |
CA (2) | CA2203363A1 (en) |
DE (1) | DE69519997T2 (en) |
DK (1) | DK0788513T3 (en) |
ES (1) | ES2154741T3 (en) |
FI (1) | FI971756A0 (en) |
HK (1) | HK1002765A1 (en) |
HU (1) | HU223006B1 (en) |
IL (1) | IL115733A (en) |
MX (1) | MX9702797A (en) |
NO (1) | NO971902D0 (en) |
NZ (2) | NZ295352A (en) |
PT (1) | PT788513E (en) |
WO (2) | WO1996012742A1 (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6893636B2 (en) | 1997-02-20 | 2005-05-17 | Biogen Idec Ma Inc. | Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics |
US7033589B1 (en) | 1997-02-20 | 2006-04-25 | Biogen Idec Ma Inc. | γ-1 anti-human CD23 monoclonal antibodies and use thereof as therapeutics |
WO2007048186A1 (en) * | 2005-10-25 | 2007-05-03 | Baker Medical Research Institute | Leukocyte-binding polypeptides and uses thereof |
CN100460015C (en) * | 2003-02-14 | 2009-02-11 | 上海张江生物技术有限公司 | Immunological regulator and application thereof |
US8465737B2 (en) | 2001-04-11 | 2013-06-18 | The Regents Of The University Of Colorado | Three-dimensional structure of complement receptor type 2 and uses thereof |
US9066925B2 (en) | 2009-07-02 | 2015-06-30 | Musc Foundation For Research Development | Methods of stimulating liver regeneration |
US9212212B2 (en) | 2006-06-21 | 2015-12-15 | The Regents Of The University Of Colorado, A Body Corporate | Targeting complement factor H for treatment of diseases |
US9259488B2 (en) | 2012-08-17 | 2016-02-16 | The Regents Of The University Of Colorado, A Body Corporate | Anti-C3d antibody conjugates and methods of detecting complement activation |
US9650447B2 (en) | 2010-05-14 | 2017-05-16 | The Regents Of The University Of Colorado, A Body Corporate | Complement receptor 2 (CR2) targeting groups |
US9815890B2 (en) | 2010-06-22 | 2017-11-14 | The Regents Of The University Of Colorado, A Body Corporate | Antibodies to the C3d fragment of complement component 3 |
US10239937B2 (en) | 2009-11-05 | 2019-03-26 | Alexion Pharmaceuticals, Inc. | Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis |
US11191851B2 (en) | 2012-08-17 | 2021-12-07 | Musc Foundation For Research Development | Anti-C3d antibody conjugates and methods of detecting complement activation |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6011138A (en) * | 1997-02-20 | 2000-01-04 | Idec Pharmaceuticals Corporation | Gamma-1 anti-human CD23 monoclonal antibodies |
AU3065999A (en) * | 1998-03-10 | 1999-09-27 | Children's Hospital Of Philadelphia, The | Compositions and methods for treatment of asthma |
GB9809839D0 (en) * | 1998-05-09 | 1998-07-08 | Glaxo Group Ltd | Antibody |
US6299875B1 (en) | 1998-06-04 | 2001-10-09 | Panacea Pharmaceuticals, Llc | Methods to block IGE binding to cell surface receptors of mast cells |
WO2000040713A1 (en) * | 1999-01-06 | 2000-07-13 | Mcmaster University | Method of preventing immune and hypersensitivity reactions |
EP1239877B1 (en) * | 1999-10-06 | 2008-01-09 | Abbott GmbH & Co. KG | Composition comprising a tnf-alpha inhibitor and an integrin alphavbeta3 receptor antagonist |
US20020028178A1 (en) * | 2000-07-12 | 2002-03-07 | Nabil Hanna | Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications |
US20030211107A1 (en) * | 2002-01-31 | 2003-11-13 | Kandasamy Hariharan | Use of CD23 antagonists for the treatment of neoplastic disorders |
US20030103971A1 (en) * | 2001-11-09 | 2003-06-05 | Kandasamy Hariharan | Immunoregulatory antibodies and uses thereof |
US20070065436A1 (en) * | 2001-01-31 | 2007-03-22 | Biogen Idec Inc. | Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies |
US20020159996A1 (en) * | 2001-01-31 | 2002-10-31 | Kandasamy Hariharan | Use of CD23 antagonists for the treatment of neoplastic disorders |
ES2322267T3 (en) * | 2003-04-09 | 2009-06-18 | Genentech, Inc. | THERAPY OF AN AUTOINMUNOLOGICAL DISEASE IN A PATIENT THAT PRESENTS AN INAPPROPRIATE RESPONSE TO A TNF-ALFA INHIBITOR. |
CA2526284C (en) * | 2003-06-25 | 2014-11-18 | Crucell Holland B.V. | Binding molecules for the treatment of myeloid cell malignancies |
AU2005229779A1 (en) | 2004-04-05 | 2005-10-20 | Universite Bordeaux 2 | Peptides and peptidomimetics binding to CD23 |
WO2006017574A1 (en) * | 2004-08-03 | 2006-02-16 | Mayo Foundation For Medical Education And Research | Improving treatments |
RU2489166C2 (en) * | 2006-04-09 | 2013-08-10 | Джинентех, Инк. | Using antibodies for treating autoimmune diseases in patient with inadequate response to tnf-alpha inhibitor |
US20090155255A1 (en) * | 2007-09-27 | 2009-06-18 | Biogen Idec Ma Inc. | Cd23 binding molecules and methods of use thereof |
CA2818712C (en) * | 2010-11-24 | 2020-11-10 | Government Of The U.S.A. Represented By The Secretary, Dept. Of Health & Human Services | Compositions and methods for treating or preventing lupus |
US10017762B2 (en) * | 2010-11-24 | 2018-07-10 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Compositions and methods for treating or preventing lupus |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989004174A1 (en) * | 1987-11-10 | 1989-05-18 | Hugh Rosen | Anti-c3bi receptor (cr3) antibodies and therapeutic composition |
EP0321842A1 (en) * | 1987-12-22 | 1989-06-28 | Kishimoto, Tadamitsu, Prof. | Soluble recombinant Fc-Epsilon-receptor, the preparation and the use thereof |
EP0358130A2 (en) * | 1988-09-06 | 1990-03-14 | Otto Prof. Dr. med. Götze | Agent with an immunosuppressive activity |
WO1990004176A1 (en) * | 1988-10-03 | 1990-04-19 | Scripps Clinic And Research Foundation | THE RECEPTOR BINDING REGION OF EBVgp350 |
WO1992001464A1 (en) * | 1990-07-19 | 1992-02-06 | The Scripps Research Institute | Inhibition of mac-1 receptor binding to fibrinogen using d30 homologs |
WO1993002108A1 (en) * | 1991-07-25 | 1993-02-04 | Idec Pharmaceuticals Corporation | Recombinant antibodies for human therapy |
WO1993009803A1 (en) * | 1991-11-22 | 1993-05-27 | The Scripps Research Institute | Factor x-derived polypeptides and anti-peptide antibodies, systems and therapeutic methods for inhibiting inflammation |
WO1994008620A1 (en) * | 1992-10-09 | 1994-04-28 | Center For Blood Research, Inc. | A subpopulation of mac-1 (cd11b/cd18) molecules which mediate neutrophil adhesion to icam-1 and fibrinogen |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4946788A (en) * | 1985-06-11 | 1990-08-07 | Ciba-Geigy Corporation | Purified immunoglobulin-related factor, novel monoclonal antibodies, hybridoma cell lines, processes and applications |
FR2599513B1 (en) * | 1986-05-27 | 1989-09-15 | Unicet Laboratoires | MONOCLONAL ANTIBODIES INHIBITING THE BINDING OF SOLUBLE IGE TO HUMAN LYMPHOCYTES, MONOCLONAL HYBRIDOMAS PRODUCING SUCH ANTIBODIES, THEIR USE |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5766943A (en) * | 1992-08-17 | 1998-06-16 | University Of Iowa Research Foundation | DNA sequences for soluble form of CD23 |
-
1995
- 1995-10-20 PT PT95936525T patent/PT788513E/en unknown
- 1995-10-20 HU HU9800339A patent/HU223006B1/en not_active IP Right Cessation
- 1995-10-20 EP EP99204301A patent/EP1018517A3/en not_active Withdrawn
- 1995-10-20 DK DK95936525T patent/DK0788513T3/en active
- 1995-10-20 EP EP95937803A patent/EP0788514A1/en not_active Withdrawn
- 1995-10-20 US US08/817,719 patent/US6627195B1/en not_active Expired - Fee Related
- 1995-10-20 WO PCT/EP1995/004110 patent/WO1996012742A1/en not_active Application Discontinuation
- 1995-10-20 NZ NZ295352A patent/NZ295352A/en unknown
- 1995-10-20 AU AU38679/95A patent/AU710369B2/en not_active Ceased
- 1995-10-20 ES ES95936525T patent/ES2154741T3/en not_active Expired - Lifetime
- 1995-10-20 KR KR10-2004-7006304A patent/KR20040058016A/en not_active Application Discontinuation
- 1995-10-20 BR BR9509498A patent/BR9509498A/en not_active Application Discontinuation
- 1995-10-20 JP JP8513642A patent/JPH10507460A/en active Pending
- 1995-10-20 AT AT95936525T patent/ATE198895T1/en not_active IP Right Cessation
- 1995-10-20 EP EP95936525A patent/EP0788513B1/en not_active Revoked
- 1995-10-20 CN CN95197075A patent/CN1171119A/en active Pending
- 1995-10-20 NZ NZ295158A patent/NZ295158A/en unknown
- 1995-10-20 CA CA002203363A patent/CA2203363A1/en not_active Abandoned
- 1995-10-20 AU AU38435/95A patent/AU698158B2/en not_active Ceased
- 1995-10-20 MX MX9702797A patent/MX9702797A/en not_active Application Discontinuation
- 1995-10-20 CA CA002203364A patent/CA2203364A1/en not_active Abandoned
- 1995-10-20 DE DE69519997T patent/DE69519997T2/en not_active Expired - Fee Related
- 1995-10-20 BR BR9509434A patent/BR9509434A/en not_active Application Discontinuation
- 1995-10-20 WO PCT/EP1995/004109 patent/WO1996012741A1/en not_active Application Discontinuation
- 1995-10-20 JP JP51350896A patent/JP3323508B2/en not_active Expired - Fee Related
- 1995-10-24 IL IL11573395A patent/IL115733A/en not_active IP Right Cessation
-
1997
- 1997-04-24 NO NO971902A patent/NO971902D0/en not_active Application Discontinuation
- 1997-04-24 FI FI971756A patent/FI971756A0/en not_active IP Right Cessation
-
1998
- 1998-02-12 HK HK98101085A patent/HK1002765A1/en not_active IP Right Cessation
-
2001
- 2001-04-25 JP JP2001127383A patent/JP2001316291A/en active Pending
-
2003
- 2003-08-04 US US10/632,852 patent/US20040022783A1/en not_active Abandoned
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989004174A1 (en) * | 1987-11-10 | 1989-05-18 | Hugh Rosen | Anti-c3bi receptor (cr3) antibodies and therapeutic composition |
EP0321842A1 (en) * | 1987-12-22 | 1989-06-28 | Kishimoto, Tadamitsu, Prof. | Soluble recombinant Fc-Epsilon-receptor, the preparation and the use thereof |
EP0358130A2 (en) * | 1988-09-06 | 1990-03-14 | Otto Prof. Dr. med. Götze | Agent with an immunosuppressive activity |
WO1990004176A1 (en) * | 1988-10-03 | 1990-04-19 | Scripps Clinic And Research Foundation | THE RECEPTOR BINDING REGION OF EBVgp350 |
WO1992001464A1 (en) * | 1990-07-19 | 1992-02-06 | The Scripps Research Institute | Inhibition of mac-1 receptor binding to fibrinogen using d30 homologs |
WO1993002108A1 (en) * | 1991-07-25 | 1993-02-04 | Idec Pharmaceuticals Corporation | Recombinant antibodies for human therapy |
WO1993009803A1 (en) * | 1991-11-22 | 1993-05-27 | The Scripps Research Institute | Factor x-derived polypeptides and anti-peptide antibodies, systems and therapeutic methods for inhibiting inflammation |
WO1994008620A1 (en) * | 1992-10-09 | 1994-04-28 | Center For Blood Research, Inc. | A subpopulation of mac-1 (cd11b/cd18) molecules which mediate neutrophil adhesion to icam-1 and fibrinogen |
Non-Patent Citations (7)
Title |
---|
B. HEYMAN ET AL.: "In vivo enhancement of the specific antibody response via the low-affinity receptor for IgE.", EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 23, no. 7, WEINHEIM, GERMANY, pages 1739 - 1742 * |
I. GROSJEAN ET AL.: "CD23/CD21 interaction is required for presentation of soluble protein antigen by lymphoblastoid B cell lines to specific CD4+ T cell clones.", EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 24, no. 12, WEINHEIM, GERMANY, pages 2982 - 2986 * |
J. AUBRY ET AL.: "CD21 is a ligand for CD23 and regulates IgE production.", NATURE, vol. 358, no. 6386, 6 August 1992 (1992-08-06), LONDON, GB, pages 505 - 507 * |
P. PIGUET ET AL.: "Effective treatment of the pulmonary fibrosis elicited in mice by bleomycin or silica with anti-CD11 antibodies.", AMERICAN REVIEW OF RESPIRATORY DISEASE, vol. 147, no. 2, USA, pages 435 - 441 * |
R. BAER ET AL.: "DNA sequence and expression of the B95-8 Epstein-Barr virus genome.", NATURE, vol. 310, 19 July 1984 (1984-07-19), LONDON, GB, pages 207 - 211 * |
S. LECOANET-HENCHOZ ET AL.: "CD23 regulates monocyte activation through a novel interaction with the adhesion molecules CD11b-CD18 and CD11c-CD18.", IMMUNITY, vol. 3, no. 1, USA, pages 119 - 125 * |
X. WU ET AL.: "Attenuation of immune-mediated glomerulonephritis with an anti-CD11b monoclonal antibody.", AMERICAN JOURNAL OF PHYSIOLOGY, vol. 264, no. 4 part 2, BETHESDA, MD, USA, pages F715 - F721, XP000562764 * |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7695940B2 (en) | 1997-02-20 | 2010-04-13 | Biogen Idec Ma Inc. | Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics |
US7033589B1 (en) | 1997-02-20 | 2006-04-25 | Biogen Idec Ma Inc. | γ-1 anti-human CD23 monoclonal antibodies and use thereof as therapeutics |
US6893636B2 (en) | 1997-02-20 | 2005-05-17 | Biogen Idec Ma Inc. | Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics |
US7223392B2 (en) * | 1997-02-20 | 2007-05-29 | Biogen Idec Ma Inc. | Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics |
US7332163B2 (en) | 1997-02-20 | 2008-02-19 | Biogen Idec Inc. | Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics |
US7438906B2 (en) | 1997-02-20 | 2008-10-21 | Biogen Idec Ma Inc. | Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics |
US8465737B2 (en) | 2001-04-11 | 2013-06-18 | The Regents Of The University Of Colorado | Three-dimensional structure of complement receptor type 2 and uses thereof |
US8858945B2 (en) | 2001-04-11 | 2014-10-14 | The Regents Of The University Of Colorado, A Body Corporate | Three-dimensional structure of complement receptor type 2 and uses thereof |
CN100460015C (en) * | 2003-02-14 | 2009-02-11 | 上海张江生物技术有限公司 | Immunological regulator and application thereof |
WO2007048186A1 (en) * | 2005-10-25 | 2007-05-03 | Baker Medical Research Institute | Leukocyte-binding polypeptides and uses thereof |
US9212212B2 (en) | 2006-06-21 | 2015-12-15 | The Regents Of The University Of Colorado, A Body Corporate | Targeting complement factor H for treatment of diseases |
US9066925B2 (en) | 2009-07-02 | 2015-06-30 | Musc Foundation For Research Development | Methods of stimulating liver regeneration |
US10239937B2 (en) | 2009-11-05 | 2019-03-26 | Alexion Pharmaceuticals, Inc. | Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis |
US9650447B2 (en) | 2010-05-14 | 2017-05-16 | The Regents Of The University Of Colorado, A Body Corporate | Complement receptor 2 (CR2) targeting groups |
US9815890B2 (en) | 2010-06-22 | 2017-11-14 | The Regents Of The University Of Colorado, A Body Corporate | Antibodies to the C3d fragment of complement component 3 |
USRE49339E1 (en) | 2010-06-22 | 2022-12-20 | The Regents Of The University Of Colorado, A Body Corporate | Antibodies to the C3D fragment of complement component 3 |
US9259488B2 (en) | 2012-08-17 | 2016-02-16 | The Regents Of The University Of Colorado, A Body Corporate | Anti-C3d antibody conjugates and methods of detecting complement activation |
US11191851B2 (en) | 2012-08-17 | 2021-12-07 | Musc Foundation For Research Development | Anti-C3d antibody conjugates and methods of detecting complement activation |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU710369B2 (en) | Binding agents for treatment of inflammatory, autoimmune or allergic diseases | |
WO1996012741A9 (en) | Binding agents to cd23 | |
JP4987484B2 (en) | Anticancer antibodies with reduced complement binding | |
Lecoanet-Henchoz et al. | CD23 regulates monocyte activation through a novel interaction with the adhesion molecules CD11b-CD18 and CD11c-CD18 | |
RU2369616C2 (en) | Fused proteins il-7 | |
US5620889A (en) | Human anti-Fas IgG1 monoclonal antibodies | |
US11779632B2 (en) | IL-2 muteins and uses thereof | |
JP2012512640A (en) | Soluble polypeptides for use in the treatment of autoimmune and inflammatory disorders | |
IL113617A (en) | Use of antibodies against lag-3 for the preparation of an immunostimulatory therapeutic composition | |
JP2021509590A (en) | The extracellular domain of the alpha subunit of the IgE Fc receptor, a pharmaceutical composition containing the same, and a method for producing the same. | |
RU2252786C2 (en) | Antibody and chemokine constructs and uses thereof in immunological disorders | |
CA2411472A1 (en) | Cd154 variants | |
EP4198050A1 (en) | Fusion protein comprising il-12 and anti-cd20 antibody and use thereof | |
Hasegawa et al. | Monoclonal antibodies to epitope of CD45R (B220) inhibit interleukin 4-mediated B cell proliferation and differentiation | |
MXPA97002772A (en) | Linking agents for the treatment of inflammatory, autoimmune or alergi treatments | |
KR20210006300A (en) | A novel pharmaceutical composition for treating allergy | |
US20030212025A1 (en) | Cd154 variants | |
MXPA97002797A (en) | Link agents a c | |
JP2008161074A (en) | CAVEOLIN-1-Fcgamma1 FUSION PROTEIN AND ITS USE | |
AU2007201053A1 (en) | CD154 Variants |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 95197075.5 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 295352 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/1997/002772 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2203364 Country of ref document: CA Ref document number: 2203364 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1995937803 Country of ref document: EP Ref document number: 1019970702697 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 1997 817768 Country of ref document: US Date of ref document: 19970711 Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1995937803 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1019970702697 Country of ref document: KR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1995937803 Country of ref document: EP |
|
WWR | Wipo information: refused in national office |
Ref document number: 1019970702697 Country of ref document: KR |